Delivery Order SPE2DB20D3304-SPE2DB25FW5K2

Award Date 2/18/25
Potential Completion Date 2/19/25
Potential Value $3.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of VYVANSE 40 mg capsules to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,649.20, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a firm fixed price with a completion date of December 17, 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at...
This federal contract award is for the delivery of VYVANSE 20 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract, with a ceiling value of $1,783.60, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is January 28, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This federal contract award is for the supply of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, and has a ceiling value of $2,169.80. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued at up to $999,999,999.00 through December...
This federal contract award is for the delivery of VYVANSE 20 MG CAPSULE 100S to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $2,809.24. The contract is a delivery order with a firm fixed price pricing type and an ultimate completion date of June 3, 2024. The contract was not designated with any set-aside requirements, indicating...
This federal contract award is for the delivery of VYVANSE 10 MG CAPSULE 100S to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $1,293.00. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is November 4, 2024. This award is not designated as a set-aside contract. The contract appears to...
This federal contract award is for the delivery of VYVANSE 70 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The $1,927.45 firm fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 24, 2025, with an ultimate completion date of January 27, 2025. The contract is not designated as a set-aside procurement. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that...
This federal contract award is for the delivery of VYVANSE 60 MG CAPSULE 100S, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on September 17, 2024, with a ceiling value of $1,724.00 and a completion date of September 18, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with a...
This federal contract award is for the delivery of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $2,358.08, was made to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 31, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award is for the delivery of VYVANSE 60 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The $1,783.60 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 18, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is for the delivery of VYVANSE 30 MG CAPSULE 100S, a pharmaceutical medication, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,344.13, is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is a $999,999,999 vehicle that provides a comprehensive range of pharmaceutical...
  • SPE2DB20D3304
    Indefinite Delivery Contract
  • SPE2DB20D3304-SPE2DB25FW5K2
    Delivery Order

This federal contract award is for the delivery of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $3,482.01. It is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating it was awarded through open competition.

Generated 5/20/25, 2:10 PM